InControl makes first atrial defibrillator implant:
This article was originally published in Clinica
Executive Summary
The first human implant of InControl's (US) Metrix atrial defibrillator was undertaken in London at the end of October. This is the first time an implantable defibrillator has been used for upper chamber therapy. InControl has tested the device in 17 humans, in four US electrophysiology laboratories since July, and plans to file an IDE for US implant trials in the next few months. Around four million people in the US and Europe suffer from atrial fibrillation and the American Heart Association estimates that more than 75,000 strokes a year in the US are associated with the rhythm disorder.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.